Increased glycemic variability in type 2 diabetes patients treated with insulin - a real-life clinical practice, continuous glucose monitoring (CGM) study

Open access


Chronic hyperglycemia is an important cause for the development of chronic complications of diabetes, but glycemic variability has emerged in recent years as an independent contributor to diabetes-related complications. Our objective was to evaluate glycemic variability in patients with T2DM treated with insulin compared with other antidiabetic drugs. In this retrospective study, we collected 24-hour continuous glucose monitoring (CGM) recording data from 95 patients with T2DM, of which 27 treated with insulin and 68 with non-insulin treatment. We calculated and compared 16 glucose variability parameters in the insulin-treated and non-insulin treated groups. Insulin treated patients had significantly higher values of parameters describing the amplitude of glucose value fluctuations (standard deviation of glucose values, percentage coefficient of variation [%CV], and mean amplitude of glycemic excursion [MAGE], p <0.05) and time-dependent glucose variability (percentage of time with glycemic values below 70 mg/dl and continuous overall net glycemic action [CONGA] at 2, 4 and 6 hours, p <0.05). In conclusion, insulin therapy in T2DM is correlated with significantly higher glycemic variability.

1. International Diabetes Federation. IDF Diabetes, 8 ed. Brussels, Belgium. International Diabetes Federation, 2017. Accesed on 04th of February 2018.

2. WHO. 10 facts on diabetes. April 2016. Accessed on 28th of December 2016.

3. American Diabetes Association. Standards of Medical Care. Diabetes Care. 2016;39 (Suppl 1): S1-112.

4. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c independent risk factor for diabetic complications. J Am Med Assoc. 2006;295(14):1707–8. DOI: 10.1001/jama.295.14.1707

5. Xu F, Zhao LH, Su JB, Chen T, Wang XQ, Chen JF et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6(1):139. DOI: 10.1186/1758-5996-6-139

6. Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273-84. DOI: 10.1016/j.diabres.2014.06.007

7. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study. Circulation. 1997;96(6):1750–4. DOI: 10.1161/01.CIR.96.6.1750

8. Monnier L, Colette C, Owens DR. Glycemic Variability: The Third Component of the Dysglycemia in Diabetes. Is It Important? How to Measure It? J Diabetes Sci Technol. 2008 Nov;2(6):1094–100. DOI: 10.1177/193229680800200618

9. American Diabetes Association. Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care 2002; 25(suppl 1): s33-s49. DOI: 10.2337/diacare.25.2007.S33

10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53. DOI: 10.1016/S0140-6736(98)07019-6

11. Czerwoniuk D, Fendler W, Walenciak L, Mlynarski W. GlyCulator: a glycemic variability calculation tool for continuous glucose monitoring data. J Diabetes Sci Technol. 2011;5(2):447–51. DOI: 10.1177/193229681100500236

12. Khadilkar KS, Bandgar T, Shivane V, Lila A, Shah N. Current concepts in blood glucose monitoring. Indian J Endocrinol Metab.2013;17(Suppl 3): S643–9. DOI: 10.4103/2230-8210.123556

13. Ramchandani N. Continuous Glucose Monitoring. Troubleshooting Common Problems. Published May 3, 2012. Accessed on 14th of December 2017.

14. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006;29(7):1486–1490. DOI: 10.2337/dc06-0293

15. DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405–8. DOI: 10.2337/db12-1610

16. Wójcicki JM. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull “M”-value. Horm Metab Res. 1995;27(1):1–5. DOI: 10.1055/s-2007-979895

17. Wójcicki JM. “J”-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res. 1995;27(1):41–2. DOI: 10.1055/s-2007-979906

18. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644–55. DOI: 10.2337/diab.19.9.644

19. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005;7(2):253–63. DOI: 10.1089/dia.2005.7.253

20. Inbody 720 User’s Manual. 1996-2004 Biospace Co, Ltd.; Available at:

21. Jellinger P, Davidson J, Blonde L, Einhorn D, Grunberger G, Handelsman Y et al. Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus: ACE/AACE Diabetes Road Map Task Force. Endocrine Practice. 2007;13(3):260-8. DOI: 10.4158/EP.13.3.260

22. American Diabetes Association. Standards of Medical Care. Diabetes Care. 2017;40(Suppl 1):S64-74.

23. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in Type 2 diabetes. Diabet Med. 2008;25(3):245–54. DOI: 10.1111/j.1464-5491.2007.02341.x

24. Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and Cardiovascular Risk: Is There a Major Link? Diabetes Care. 2016;39(Suppl.2):S205-9. DOI: 10.2337/dcS15-3014

25. Takeishi S, Mori A, Hachiya H, Yumura T, Ito S, Shibuya T et al. Hypoglycemia and glycemic variability are associated with mortality in non-intensive care unit hospitalized infectious disease patients with diabetes mellitus. J Diabetes Investig 2016;7(3):429–35. DOI: 10.1111/jdi.12436

26. Tricco AC, Ashoor HM, Soobiah C, Hemmelgarn B, Moher D, Hutton B et al. Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis. Syst Rev 2013;2:73. DOI: 10.1186/2046-4053-2-73

27. Bajaj HS, Venn K, Ye C, Patrick A, Kalra S, Khandwala H et al. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Diabetes Care. 2017;40(2):194-200. DOI: 10.2337/dc16-1582

28. Suh S, Kim JH. Glycemic Variability: How Do We Measure It and Why Is It Important? Diabetes Metab J. 2015;39(4):273–82. DOI: 10.4093/dmj.2015.39.4.273

29. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–7. DOI: 10.1001/jama.295.14.1681

30. The FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016 Jun;39(6):973-81. DOI: 10.2337/dc15-2782

31. Kovatchev B, Cobelli C. Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes. Diabetes Care. 2016; 39(4): 502-10. DOI: 10.2337/dc15-2035

32. Fabris C, Facchinetti A, Fico G, Sambo F, Arredondo MT, Cobelli C; MOSAIC EU Project Consortium. Parsimonious Description of Glucose Variability in Type 2 Diabetes by Sparse Principal Component Analysis. J Diabetes Sci Technol. 2015;10(1):119-24. DOI: 10.1177/1932296815596173

33. Monnier L, Colette C, Wojtusciszyn A, Dejager S, Renard E, Molinari N et al. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care. 2017;40(7):832-8. DOI: 10.2337/dc16-1769

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 86 86 7
PDF Downloads 61 61 5